These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2463 related articles for article (PubMed ID: 7994925)

  • 1. Human immune response to DNP-modified autologous cells after treatment with a DNP-conjugated melanoma vaccine.
    Sato T; Maguire HC; Mastrangelo MJ; Berd D
    Clin Immunol Immunopathol; 1995 Jan; 74(1):35-43. PubMed ID: 7994925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dinitrophenyl-modified autologous melanoma vaccine induces a T cell response to hapten-modified, melanoma peptides.
    Sato T; Bullock TN; Eisenlohr LC; Mastrangelo MJ; Berd D
    Clin Immunol Immunopathol; 1997 Dec; 85(3):265-72. PubMed ID: 9400626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active specific immunotherapy with hapten-modified autologous melanoma cell vaccine.
    Sato T
    Cancer Immunol Immunother; 1996 Nov; 43(3):174-9. PubMed ID: 9001571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. M-Vax: an autologous, hapten-modified vaccine for human cancer.
    Berd D
    Expert Rev Vaccines; 2004 Oct; 3(5):521-7. PubMed ID: 15485331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
    Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
    Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous, hapten-modified vaccine as a treatment for human cancers.
    Berd D; Kairys J; Dunton C; Mastrangelo MJ; Sato T; Maguire HC
    Semin Oncol; 1998 Dec; 25(6):646-53. PubMed ID: 9865679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation markers on T cells infiltrating melanoma metastases after therapy with dinitrophenyl-conjugated vaccine.
    Berd D; Maguire HC; Mastrangelo MJ; Murphy G
    Cancer Immunol Immunother; 1994 Sep; 39(3):141-7. PubMed ID: 7923243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas.
    Crowley NJ; Slingluff CL; Darrow TL; Seigler HF
    Cancer Res; 1990 Feb; 50(3):492-8. PubMed ID: 2404572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine.
    Berd D; Sato T; Maguire HC; Kairys J; Mastrangelo MJ
    J Clin Oncol; 2004 Feb; 22(3):403-15. PubMed ID: 14691123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results, and possible mechanisms of action.
    Mitchell MS; Harel W; Kan-Mitchell J; LeMay LG; Goedegebuure P; Huang XQ; Hofman F; Groshen S
    Ann N Y Acad Sci; 1993 Aug; 690():153-66. PubMed ID: 8368734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine.
    Sensi M; Farina C; Maccalli C; Lupetti R; Nicolini G; Anichini A; Parmiani G; Berd D
    J Clin Invest; 1997 Feb; 99(4):710-7. PubMed ID: 9045874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A human melanoma cell line, recognized by both HLA class I and class II restricted T cells, is capable of initiating both primary and secondary immune responses.
    Olsen AC; Fossum B; Kirkin AF; Zeuthen J; Gaudernack G
    Scand J Immunol; 1995 Apr; 41(4):357-64. PubMed ID: 7899823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.
    Lotem M; Machlenkin A; Hamburger T; Nissan A; Kadouri L; Frankenburg S; Gimmon Z; Elias O; David IB; Kuznetz A; Shiloni E; Peretz T
    Clin Cancer Res; 2009 Aug; 15(15):4968-77. PubMed ID: 19602547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melanoma-specific cytotoxic T cells generated from peripheral blood lymphocytes. Implications of a renewable source of precursors for adoptive cellular immunotherapy.
    Slingluff CL; Darrow TL; Seigler HF
    Ann Surg; 1989 Aug; 210(2):194-202. PubMed ID: 2787972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A B7-1-transfected human melanoma line stimulates proliferation and cytotoxicity of autologous and allogeneic lymphocytes.
    Sulé-Suso J; Arienti F; Melani C; Colombo MP; Parmiani G
    Eur J Immunol; 1995 Oct; 25(10):2737-42. PubMed ID: 7589065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma.
    Mukherji B; Guha A; Chakraborty NG; Sivanandham M; Nashed AL; Sporn JR; Ergin MT
    J Exp Med; 1989 Jun; 169(6):1961-76. PubMed ID: 2471770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous melanoma vaccine induces inflammatory responses in melanoma metastases: relevance to immunologic regression and immunotherapy.
    Murphy GF; Radu A; Kaminer M; Berd D
    J Invest Dermatol; 1993 Mar; 100(3):335S-341S. PubMed ID: 8440919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective expansion of a specific anti-tumor CD8+ cytotoxic T lymphocyte clone in the bulk culture of tumor-infiltrating lymphocytes from a melanoma patient: cytotoxic activity and T cell receptor gene rearrangements.
    Gervois N; Heuze F; Diez E; Jotereau F
    Eur J Immunol; 1990 Apr; 20(4):825-31. PubMed ID: 1971794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
    Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
    Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
    Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
    Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 124.